AKT1 and cancer: With this work, we show for the first time, that depletion of ANXA2 in cancer cells leads to enhanced activation of AKT in response to either EGF/EGFR activation or oncogenic H-RasV12 transformation (Figure 1 and Supplementary Materials Figure S1).